Current Treatment Options in Neurology

, Volume 9, Issue 1, pp 14–22 | Cite as

Chronic daily headache in the pediatric population


Opinion statement

Very limited long-term follow-up data exist for the population of children and adolescents with chronic daily headache (CDH). One abstracted report discusses short-term follow-up on 24 adolescents (peak age 13 years) with CDH; in a 6-month follow-up, more than 50% experienced a reduction of 75% or more in headache frequency, and one third showed an improvement of greater than 90% in headache frequency. A wide variety of preventive agents were used, but amitriptyline and topiramate provided the largest percentage of successful outcomes. With an improving classification scheme, we have the possibility of using multicenter studies to elucidate whether the clinical patterns seen by experienced observers translate into rational differentiation of treatment approaches. If the entities of CDH are, indeed, different, then therapeutic, prophylactic, and behavioral trials could guide us in offering a more evidence-based approach to the treatment of this fascinating, yet sometimes debilitating condition.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Viswanathan V, Bridges SJ, Whitehouse W, Newton RW: Childhood headaches: discrete entities or continuum? Dev Med Child Neurol 1998, 40:544–550.PubMedCrossRefGoogle Scholar
  2. 2.
    Abu-Arafeh I, Russell G: Prevalence of headache and migraine in schoolchildren. Br Med J 1994, 309:765–769.Google Scholar
  3. 3.
    Lipton RB, Stewart WF: Prevalence and impact of migraine. Neurol Clin 1997, 15:1–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Castillo J, Muñoz P, Guitera V, Pascual J: Epidemiology of chronic daily headache in the general population. Headache 1999, 39:190–196.PubMedCrossRefGoogle Scholar
  5. 5.
    Wang SJ, Fuh JL, Lu SR, Juang KD: Chronic daily headache in adolescents: prevalence, impact, and medication overuse. Neurology 2006, 66:193–197.PubMedCrossRefGoogle Scholar
  6. 6.
    Powers SW, Patton SR, Hommel KA, Hershey AD: Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses. Pediatrics 2003, 112:e1–e5.PubMedCrossRefGoogle Scholar
  7. 7.
    Guitera V, Munoz P, Castillo J, Pascual J: Quality of life in chronic daily headache. Neurology 2002, 58:1062–1065.PubMedGoogle Scholar
  8. 8.
    Headache Classification Subcommittee of the International Headache Society: The international classification of headache disorders. Cephalalgia 2004, 24(Suppl 1):1–160.Google Scholar
  9. 9.
    Edmeads J, Mackell JA: The economic impact of migraine: an analysis of direct and indirect costs. Headache 2002, 42:501–509.PubMedCrossRefGoogle Scholar
  10. 10.
    Mathew NT, Kurman R, Perez F: Drug induced refractory headache—clinical features and management. Headache 1990, 30:634–638.PubMedCrossRefGoogle Scholar
  11. 11.
    Meskunas CA, Tepper SJ, Rapoport AM, et al.: Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 2006, 46:766–772.PubMedCrossRefGoogle Scholar
  12. 12.
    Guitera V, Muñoz P, Castillo J, Pascual J: Transformed migraine: a proposal for the modification of its diagnostic criteria based on recent epidemiological data. Cephalalgia 1999, 19:847–850.PubMedCrossRefGoogle Scholar
  13. 13.
    Silberstein S, Lipton R: Chronic daily headache including transformed migraine, chronic tension-type headache, and medication over-use. In Wolff’s Headache and Other Head Pain. Edited by Silberstein SD, Lipton RB, Dalessio DJ. New York: Oxford University Press; 2001:247–282.Google Scholar
  14. 14.
    Bigal ME, Tepper SJ, Sheftell FD, et al.: Chronic daily headache: correlation between the 2004 and the 1988 International Headache Society diagnostic criteria. Headache 2004, 44:684–691.PubMedCrossRefGoogle Scholar
  15. 15.
    Bigal ME, Rapoport AM, Tepper SJ, et al.: The classification of chronic daily headache in adolescents—a comparison between the second edition of the international classification of headache disorders and alternative diagnostic criteria. Headache 2005, 45:582–589.PubMedCrossRefGoogle Scholar
  16. 16.
    Bigal ME, Tepper SJ, Sheftell FD, et al.: Field testing alternative criteria for chronic migraine. Cephalalgia 2006, 26:477–482.PubMedCrossRefGoogle Scholar
  17. 17.
    Hershey AD, Powers SW, Bentti AL, et al.: Characterization of chronic daily headaches in children in a multidisciplinary headache center. Neurology 2001, 56:1032–1037.PubMedGoogle Scholar
  18. 18.
    Olesen J, Bousser MG, Diener HC, et al.: New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006, 26:742–746.PubMedCrossRefGoogle Scholar
  19. 19.
    Gladstein J, Holden EW: Chronic daily headache in children and adolescents: a 2-year prospective study. Headache 1996, 36:349–351.PubMedCrossRefGoogle Scholar
  20. 20.
    Koenig MA, Gladstein J, McCarter RJ, et al.: Chronic daily headache in children and adolescents presenting to tertiary headache clinics. Headache 2002, 42:491–500.PubMedCrossRefGoogle Scholar
  21. 21.
    Seshia SS: Chronic daily headache in children and adolescents. Can J Neurol Sci 2004, 31:319–323.PubMedGoogle Scholar
  22. 22.
    Redillas C, Solomon S: Prophylactic pharmacological treatment of chronic daily headache. Headache 2000, 40:83–102.PubMedCrossRefGoogle Scholar
  23. 23.
    Rothrock JF: Management of chronic daily headache utilizing a uniform treatment pathway. Headache 1999, 39:650–653.PubMedCrossRefGoogle Scholar
  24. 24.
    Magnusson JE, Riess CM, Becker WJ: Effectiveness of a multidisciplinary treatment program for chronic daily headache. Can J Neurol Sci 2004, 31:72–79.PubMedGoogle Scholar
  25. 25.
    Lewis D, Ashwal S, Hershey A, et al.: Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004, 63:2215–2224.PubMedGoogle Scholar
  26. 26.
    Hershey AD, Powers SW, Bentti AL, Degrauw TJ: Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache 2000, 40:539–549.PubMedCrossRefGoogle Scholar
  27. 27.
    Bartolini M, Silvestrini M, Taffi R, et al.: Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005, 28:277–279.PubMedCrossRefGoogle Scholar
  28. 28.
    Brandes JL, Saper JR, Diamond M, et al.: Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004, 291:965–973.PubMedCrossRefGoogle Scholar
  29. 29.
    Hershey AD, Powers SW, Vockell AL, et al.: Effectiveness of topiramate in the prevention of childhood headaches. Headache 2002, 42:810–818.PubMedCrossRefGoogle Scholar
  30. 30.
    Silvestrini M, Bartolini M, Coccia M, et al.: Topiramate in the treatment of chronic migraine. Ceephalalgia 2003, 23:820–824.CrossRefGoogle Scholar
  31. 31.
    Borzy JC, Koch TK, Schimschock JR: Effectiveness of topiramate in the treatment of pediatric chronic daily headache. Pediatric Neurol 2005, 33:314–316.CrossRefGoogle Scholar
  32. 32.
    Mathew NT, Saper JR, Silberstein SD, et al.: Migraine prophylaxis with divalproex. Arch Neurol 1995, 52:281–286.PubMedGoogle Scholar
  33. 33.
    Freitag F, Diamond S, Diamond ML, Urban GJ: Divalproex in the long-term treatment of chronic daily headache. Headache 2001, 41:271–278.PubMedCrossRefGoogle Scholar
  34. 34.
    Freitag F, Collins SD, Carlson HA, et al.: A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002, 58:1652–1659.PubMedGoogle Scholar
  35. 35.
    Caruso JM, Brown WD, Exil G, Gascon GG: The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Headache 2000, 40:672–676.PubMedCrossRefGoogle Scholar
  36. 36.
    Mathew NT, Rapoport A, Saper J, et al.: Efficacy of gabapentin in migraine prophylaxis. Headache 2001, 41:119–128.PubMedCrossRefGoogle Scholar
  37. 37.
    Bille B, Ludvigsson J, Sanner G: Prophylaxis of migraine in children. Headache 1977, 17:61–63.PubMedCrossRefGoogle Scholar
  38. 38.
    Levinstein B: A comparative study of cyproheptadine, amitriptyline, and propranolol in the treatment of adolescent migraine. Cephalalgia 1991, 11:122–123.Google Scholar
  39. 39.
    Ludvigsson J: Propranolol used in prophylaxis of migraine in children. Acta Neurol Scand 1974, 50:109–115.PubMedCrossRefGoogle Scholar
  40. 40.
    Ziegler DK, Hurwitz A: Propranolol and amitriptyline in prophylaxis of migraine. Arch Neurol 1993, 50:825–830.PubMedGoogle Scholar
  41. 41.
    Hämäläinen ML, Hoppu K, Valkeila E, Santavuori P: Ibuprofen or acetaminophen for the acute treatment of migraine in children. Neurology 1997, 48:103–107.PubMedGoogle Scholar
  42. 42.
    Lewis D, Kellstein D, Dahl G, et al.: Children’s ibuprofen suspension for pediatric migraine. Ann Neurol 2001, 50 (Suppl 1):S93.CrossRefGoogle Scholar
  43. 43.
    Vasconcellos E, Pina-Garza JE, Millan EJ, Warner JS: Analgesic rebound headache in children and adolescents. J Child Neurol 1998, 13:443–447.PubMedCrossRefGoogle Scholar
  44. 44.
    Lipton RB, Stewart WF, Cady R, et al.: Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 2000, 40:783–791.PubMedCrossRefGoogle Scholar
  45. 45.
    Cady RC, Ryan R, Jhingran P, et al.: Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med 1998, 9:1013–1018.CrossRefGoogle Scholar
  46. 46.
    Cobb JP, Mindrinos MN, Miller-Graziano C, et al.: Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A 2005, 102:4801–4806.PubMedCrossRefGoogle Scholar
  47. 47.
    Schoenen J, Jacquy J, Lenaerts M: Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology 1998, 50:466–470.PubMedGoogle Scholar
  48. 48.
    Sandor PS, Di Clemente L, Coppola G, et al.: Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005, 64:713–715.PubMedGoogle Scholar
  49. 49.
    Pfaffenrath V, Wessely P, Meyer C, et al.: Magnesium in the prophylaxis of migraine-a double-blind, placebo-controlled study. Cephalalgia 1996, 16:436–440.PubMedCrossRefGoogle Scholar
  50. 50.
    Vogler BK, Pittler MH, Ernst E: Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998, 18:704–708.PubMedCrossRefGoogle Scholar
  51. 51.
    Lipton RB, Gobel H, Einhaupl KM, et al.: Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004, 63:2240–2244.PubMedGoogle Scholar
  52. 52.
    Pothmann R, Danesch U: Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache 2005, 45:196–203.PubMedCrossRefGoogle Scholar
  53. 53.
    Powers SW, Hershey AD: Biofeedback for childhood migraine. In Current Management in Child Neurology, end 2. Edited by Maria BL. Hamilton, Ontario: B.C. Decker; 2002:83–85.Google Scholar
  54. 54.
    Powers SW, Andrasik F: Biobehavioral treatment, disability, and psychological effects of pediatric headache. Pediatr Ann 2005, 34:461–465.PubMedGoogle Scholar
  55. 55.
    Juang KD, Wang SJ, Fuh JL, et al.: Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache 2000, 40:818–823.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Division of Neurology, Cincinnati Children’s Hospital Medical CenterHeadache CenterCincinnatiUSA

Personalised recommendations